logo-loader
Indivior

Indivior falls again as US court ruling clears way for launch of Suboxone generic

Suboxone is Indivor’s big money-maker, but two generic versions could hit the market as early as next Tuesday after the latest ruling from a US appeals court

suboxone
Indivior is adamant that the generics infringe on its patents and is taking its case to the Supreme Court

Indivior PLC (LON:INDV) has been dealt another blow in its bid to protect its star drug after a US court ruling cleared the way for two rivals to launch their generic versions of the opioid addiction next week.

The drugmaker has been aggressively defending Suboxone, which makes up the bulk of its annual revenue, for several years now, claiming that cut-price treatments from Dr Reddy’s and Alvogen infringe on its patents.

READ: Federal court rejects Suboxone appeal

But last week, a US appeals court ratified an earlier decision by a district court in Delaware that gave the generics the all-clear.

Indivior is taking its case to the Supreme Court, the highest court in the US, and had hoped to delay the launch of the copycat versions until after then.

But that request has been rejected by the appeals court, which has told Indian giant Dr Reddy’s and Alvogen that they can start selling their drugs into the market next Tuesday (19 February).

Dr Reddy’s not averse to an ‘at-risk’ launch

Any launch would be on an ‘at-risk’ basis though – when litigation is still going – as Indivior is still trying to protect its intellectual property (IP) through a court in New Jersey as well as the Supreme Court.

That wasn’t a concern for Dr Reddy’s last summer though when it briefly launched its version ‘at-risk’ and took a decent chunk out of Suboxone’s market share despite only being available for a few hours.

Indivior shares were down 2.2% to 104.7p. Last summer they were changing hands for more than 500p.

Quick facts: Indivior

Price: £0.57

Market: LSE
Market Cap: £414.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Arcadia Biosciences makes major progress on its hemp venture...

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Raj Ketkar tells Proactive the California-based company expects to “significantly scale revenues in 2020” as it reported financial and business results for the second quarter and first half of 2019. Ketkar says the agricultural innovation company made...

2 days, 10 hours ago

RNS

Director/PDMR Shareholding

5 days, 17 hours ago

Director/PDMR Shareholding

1 week, 3 days ago

Director/PDMR Shareholding

1 week, 4 days ago

Director/PDMR Shareholding

1 week, 6 days ago

Holding(s) in Company

2 weeks, 4 days ago

Total Voting Rights

2 weeks, 4 days ago

Directorate Changes

2 weeks, 5 days ago

Half-year Report

2 weeks, 5 days ago

2 min read